Analyst Price Targets — HIMS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 8:36 am | — | Deutsche Bank | $28.00 | $23.47 | TheFly | Hims & Hers price target raised to $28 from $25 at Deutsche Bank |
| March 9, 2026 3:24 pm | Ryan MacDonald | Needham | $30.00 | $22.35 | StreetInsider | Needham Upgrades Hims and Hers (HIMS) to Buy |
| March 9, 2026 12:46 pm | — | Oppenheimer | $12.50 | $21.58 | StreetInsider | BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) amid Novo partnership |
| February 24, 2026 5:34 pm | — | Barclays | $25.00 | $15.91 | TheFly | Hims & Hers price target lowered to $25 from $48 at Barclays |
| February 24, 2026 1:24 pm | Craig Hettenbach | Morgan Stanley | $21.00 | $14.38 | TheFly | Hims & Hers price target lowered to $21 from $40 at Morgan Stanley |
| February 24, 2026 1:01 pm | — | Evercore ISI | $24.00 | $14.10 | TheFly | Hims & Hers price target lowered to $24 from $33 at Evercore ISI |
| February 24, 2026 12:22 pm | Jailendra Singh | Truist Financial | $18.00 | $15.51 | TheFly | Hims & Hers price target lowered to $18 from $37 at Truist |
| February 24, 2026 10:58 am | — | Leerink Partners | $17.50 | $15.51 | TheFly | Hims & Hers price target lowered to $17.50 from $20 at Leerink |
| February 10, 2026 3:41 pm | George Hill | Deutsche Bank | $31.00 | $18.25 | TheFly | Hims & Hers price target lowered to $31 from $42 at Deutsche Bank |
| February 9, 2026 1:26 pm | Michael Cherny | Leerink Partners | $20.00 | $17.35 | StreetInsider | Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners |
Latest News for HIMS
Expand NYSE: HIMS Hims & Hers Health Today's Change (11.28%) $2.74 Current Price $27.03 Key Data Points Market Cap $5.5B Day's Range $24.77 - $27.81 52wk Range $13.74 - $70.43 Volume 2.5M Avg Vol 35M Gross Margin 60.86% Hims & Hers Health (HIMS +11.28%), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as…
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, despite clinical evidence for efficacy being limited.
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regulatory status of several wellness peptides used in compounding pharmacies. The FDA announced it will hold meetings on July 23 and 24 with its Pharmacy Compounding Advisory Committee to discuss whether multiple…
Shares of Hims & Hers Health rose more than 7% on Thursday as analysts said the U.S. drug regulator's consideration to allow compounding pharmacies to manufacture popular peptides could benefit the telehealth firm in the long run.
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HIMS.
U.S. House Trading
No House trades found for HIMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.